Peter Bornstein, MD
St. Paul Infectious Disease Associates, Ltd
Peter Bornstein, MD, is Partner and Consultant in Infectious Diseases at St. Paul Infectious Disease Associates, Ltd in Minnesota. He spends most of his time seeing critically ill and chronically ill patients. Dr. Bornstein is the Chairman of the Antibiotic Subcommittee of the Pharmacy and Therapeutic Committee of a four hospital consortium, HealthEast. He is also the Chairman of Infection Control at HealthEast, responsible for oversight of infection control activities. Dr. Bornstein formerly served a voluntary position as Medical Director of Amigos de las Americas, an international non-profit public health and community development agency based in Houston. He is the current board chair of Minnesota Physician Services. Since 1997, Dr. Bornstein has been named a "Top Doc" in Infectious Diseases in a poll of physicians and nurses for Minneapolis-St. Paul Magazine. Dr. Bornstein is currently enrolled in the MBA program at the Carlson School of Management at the University of Minnesota. (This is me - Update Profile)
| 1993 - present | Partner St. Paul Infectious Disease Associates, Ltd |
|---|---|
| 1991 - 1993 | Fellow, Infectious Diseases Northwestern University Medical School |
| 1987 - 1991 | Resident Physician Henry Ford Hospital |
GLG Study Groups with Peter Bornstein, MD(?)
| Study Group Name | Members |
|---|---|
| Cubicin Prescribers (US) | 118 |
| Infectious Diseases Physicians (US) | 912 |
GLG NewsSM Analyses by Peter Bornstein, MD(?)
With a plethora of expensive Electronic Medical Record (EMR) programs on the market, the lack of a standard or interoperability has kept many practices on the sidelines. Moreover, systems that do use EMRs, often cannot exchange that information with other EMRs. Google could leverage its technology,...
The lack of improvement with use of antibiotics or steroids will make primary care providers less likely to prescribe these agents. However, they will have to spend significant time explaining to patients why they have changed their practice.
A randomized and blinded study shows a once-a-day formulation of amoxicillin is non-inferior to four times a day penicillin in the treatment of pharyngitis and tonsillitis caused by Group A Beta-hemolytic streptococci. While once-a-day treatment is generally preferred over multidose treatments, will...
Abbott Laboratories, one of the largest pharmaceutical companies in the world, enters into an agreement with a privately-held biotech firm, Enanta, to develop and commercialize Hepatitis C virus (HCV) protease inhibitors (PIs). HCV PIs would be a new drug class in the treatment of HCV.
GLG InstituteSM Seminars with Peter Bornstein, MD(?)
Recent Seminars
Request a project with Peter Bornstein, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms